What is DYAI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DYAI?

P/E (TTM) is n/a and 52-week range is $0.34 to $1.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DYAI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DYAI?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-762M, EPS (TTM) near $-0.23 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Dyadic International Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Jupiter, Florida, US, 36.4M shares outstanding, ISIN US26745T1016 when available from company profile and filing metadata.

Chartloom

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida. The company went IPO on 2004-11-05. The firm's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The firm has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Employees

Website

dyadic.com/

IPO

2004-11-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)